National Rheumatology Summit. Place of adalimumab in current pharmacotherapy strategy for rheumatoid arthritis

Abstract

The rheumatoid arthritis (RA) session was held in Sochi on April 25, 2015, within the framework of the National Rheumatology Summit. Leading Russian and foreign experts discussed the general provisions of the 2013 European League Against Rheumatism (EILAR) guidelines and the Association of Rheumatologists of Russia (ARR) ones for the management of RA, considered optimal usage periods for biological agents to achieve the goals of treatment for early and long-term RA, by using adalimumab (ADA) as an example, and analyzed the results of trials of the efficiency and safety of combined therapy with ADA and methotrexate. Particular emphasis was placed on the results of introducing the treatto-target concept into Russian clinical practice and on those of monitoring RA patients.

Keywords

• national rheumatology summit
• rheumatoid arthritis
• treat-to-target (t2t) concept
• biological agents
• tumor necrosis factor-α inhibitors
• adalimumab
• methotrexate